S1P in Tumor Microenvironment and Modulation of Anti-Tumor-Directed T-Cell Responses

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) shows promise for solid cancers.
• Clinical success correlates with specific T-cell phenotypes, like CD8+ TILs with progenitor stem-cell-like profiles (CD39- CD69-).

Purpose of the Study:

• To review the role of the sphingosine-1-phosphate (S1P) axis in ACT and anti-tumor immunity.
• To explore S1P's dual function in the tumor microenvironment (TME) and its impact on T-cell fitness and tumor progression.

Main Methods:

• Literature review focusing on the S1P axis, T-cell phenotypes, and the TME.
• Analysis of biological antagonism between CD69 and S1P receptor 1 (S1PR1).
• Examination of S1P's role in mitochondrial fitness and T-cell energetics.

Main Results:

• The S1P axis, particularly S1PR1, is crucial for T-cell retention, recirculation, and immune surveillance.
• S1P acts as a double-edged sword in the TME, promoting angiogenesis and vascular mimicry while potentially enhancing T-cell fitness.
• Clinical trials are investigating S1P modulation for anti-tumor responses and using S1P as a treatment outcome marker.

Conclusions:

• The S1P axis is a key regulator of T-cell function and a critical factor in the efficacy of ACT for solid tumors.
• Targeting the S1P axis offers potential therapeutic strategies to enhance anti-tumor immunity and improve patient outcomes.